IP Verse

Methods Of Treating Cancers Using Pd-1 Axis Binding Antagonists And Taxanes - EP3083686

The patent EP3083686 was granted to F Hoffmann LA Roche on Mar 22, 2023. The application was originally filed on Dec 17, 2014 under application number EP14824700A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3083686

F HOFFMANN LA ROCHE
Application Number
EP14824700A
Filing Date
Dec 17, 2014
Status
Patent Maintained As Amended
Feb 17, 2023
Grant Date
Mar 22, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ARES TRADINGJul 23, 2020MERCK SERONOADMISSIBLE
GLAXOSMITHKLINEJul 23, 2020CHIAPPINELLIADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONWO2010077634
EXAMINATIONWO2013019906
INTERNATIONAL-SEARCH-REPORTWO2013019906
OPPOSITIONCA2896797
OPPOSITIONUS8217149
OPPOSITIONWO2009089149
OPPOSITIONWO2013079174
OPPOSITIONWO2014151006
OPPOSITIONWO2015176033

Non-Patent Literature (NPL) Citations (28) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- JIANG JINGWEI ET AL, "Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY DEC 2013, (201312), vol. 18, no. 6, ISSN 1437-7772, pages 1005 - 1013-
EXAMINATION- ZHANG ET AL, "Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis", MOLECULAR IMMUNOLOGY, PERGAMON, GB, (20071024), vol. 45, no. 5, doi:10.1016/J.MOLIMM.2007.08.013, ISSN 0161-5890, pages 1470 - 1476, XP022402180
EXAMINATION- AL-FARSI ABDULAZIZ ET AL, "Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line.", FRONTIERS IN ONCOLOGY, (20140601), vol. 4, pages 1 - 5, XP002774726
OPPOSITION- Anonymous, "Study NCT01454102 Submitted Date: July 9, 2014", ClinicalTrials.gov, (20140709), pages 1 - 6, (20210607), XP055810845-
OPPOSITION- Anonymous, "Study NCT01633970 Submitted Date: November 4, 2013", ClinicalTrials.gov, (20131104), pages 1 - 4, (20210607), XP055810850-
OPPOSITION- Anonymous, "What Is Lung Cancer? Types of Lung Cancer", American Cancer Society, (20200713), pages 1 - 3, URL: https://www.cancer.org/cancer/lung-cancer/about/what- is.html, (20210617), XP055814910-
OPPOSITION- AZVOLINSKY A., "AACR: Immunotherapy Antibody Has Activity in Range of Solid Tumors", Cancer Network, (20130000), URL: https://www.cancernetwork.com/view/aacr- immunotherapy-antibody-has-activity-ranqe-solid-tumors-
OPPOSITION- Boehm Darryl, "Paclitaxel Premedication Regimens", Journal of the National Cancer Institute, (19960403), vol. 88, no. 7, pages 463 - 465, XP055814905-
OPPOSITION- Crawford et al., Journal of Thorarcic Oncology, Vol. 8, No. 12, 2013, pp 1510-1518-
OPPOSITION- Declaration of Dr. M. Ballinger-
OPPOSITION- Declaration of Dr. Yi-
OPPOSITION- Drillon Alexander, Et Al, "Squamous- Cell Carcinomas of the Lung: Emerging Biology, Controversies, and the Promise of Targeted Therapy", The Lancet (Oncology), (20121001), vol. 13, pages e418 - e426, XP055814877-
OPPOSITION- FORDE PM et al., "What lies within: novel strategies in immunotherapy for non-small cell lung cancer", Oncologist, (20130000), vol. 18, no. 11, doi:10.1634/theoncologist.2013-0171, pages 1203 - 1213-
OPPOSITION- Goffin John, Et Al, "First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review", Journal of Thoracic Oncology, (20100201), vol. 5, no. 2, pages 260 - 274, XP055814918-
OPPOSITION- History of Changes for Study: NCT01633970-
OPPOSITION- Peng J, Et Al, "Poster Presentations: Ovarian Cancer CHEMOTHERAPY FOR OVARIAN CANCER INDUCES PD-L1 OVEREXPRESSION VIA NF-KB SIGNAL PATHWAY", International Journal of Gynecological Cancer, (20131001), vol. 23, no. 8-1, pages 1 - 1, XP055814883-
OPPOSITION- Roy S Herbst et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov.27,515(7528):563-7. doi.10.1038/nature14011-
OPPOSITION- SOCINSKI MA, BONDARENKO I, KARASEVA NA et al., "Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small- cell lung cancer: final results of a phase III trial", J Clin Oncol, (20120000), vol. 30, no. 17, doi:10.1200/JCO.2011.39.5848, pages 2055 - 2062-
OPPOSITION- Socinski M A, Et Al, "Results of a Randomized, Phase III Trial of Nab-Paclitaxel (nab-P) and Carboplatin (C) Compared with Cremophor-based Paclitaxel (P) and Carboplatin as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC", Journal of Clinical Oncology, (20100101), vol. 28, no. 18, pages 1 - 3, XP055814879-
OPPOSITION- Tan Winston W, "Non-Small Cell Lung Cancer (NSCLC): Practice Essentials, Background, Pathophysiology", Medscape, (20200605), pages 1 - 14, Medscape, URL: https://emedicine.medscape.com/article/279960-overview, (20210617), XP055814915-
OPPOSITION- Wendling report on “CheckMate 012"-
OPPOSITION- BERGER MJ et al., "Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction", Support Care Cancer, (20120000), vol. 20, no. 9, doi:10.1007/s00520-011-1303-9, pages 1991 - 1997, XP035094550
OPPOSITION- ZHANG et al., "Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis", Molecular Immunology, (20070000), vol. 45, no. 5, doi:10.1016/j.molimm.2007.08.013, pages 1470 - 1476, XP022402180
OPPOSITION- POWLES T et al., "MPDL3280A (anti-PD-Ll) treatment leads to clinical activity in metastatic bladder cancer", Nature, (20140000), vol. 515, no. 7528, doi:10.1038/nature13904, pages 558 - 562, XP055207741
OPPOSITION- ASCIERTO et al., "Clinical Experiences With Anti- CD 137 and Anti-PD1 Therapeutic Antibodies", Seminars in Oncology, (20100000), vol. 37, no. 5, doi:10.1053/j.seminoncol.2010.09.008, pages 508 - 516, XP008175440
OPPOSITION- SOCINSKI MA, BONDARENKO I, KARASEVA NA et al., "Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small- cell lung cancer: final results of a phase III trial", J Clin Oncol, (20120000), vol. 30, no. 17, doi:10.1200/JCO.2011.39.5848, pages 2055 - 2062, XP055310043
OPPOSITION- SPIGEL et al., "Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC", Journal of Clinical Oncology, (20130000), vol. 31, no. 15, doi:10.1200/jco.2013.31.15_suppl.8008, page 8008, XP009508002
OPPOSITION- FORDE PM et al., "What lies within: novel strategies in immunotherapy for non-small cell lung cancer", Oncologist, (20130000), vol. 18, no. 11, doi:10.1634/theoncologist.2013-0171, pages 1203 - 1213, XP055286800

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents